

Metivier, Jacob

From: Tina_Still@eisai.com
Sent: Friday, January 20, 2023 1:43 PM
To: AGO - High Cost Prescription Drugs
Cc: Irfan_Ahmed@eisai.com; Gary_Smith@eisai.com
Subject: Notice pursuant to 18 V.S.A § 4637(b)

Follow Up Flag: Follow up
Flag Status: Flagged

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.



January 20, 2023

To Whom It May Concern:

Eisai Inc. is providing notice within three days of the release of the new drug LEQEMBI™ into the commercial market. Eisai Inc. hereby notifies the Vermont Attorney General of the following new prescription drug pursuant to 18 V.S.A. § 4637(b):

NDC Number	Product Description	Date of Commercial Availability	Wholesale Acquisition Cost
62856-0212-01	Leqembi 200mg/2ml	January 18, 2023	\$254.81
62856-0215-01	Leqembi 500mg/5ml	January 18, 2023	\$637.02

If you have any questions, please contact me.

Sincerely,

Tina Still

Associate Director
Market Access Pricing
200 Metro Blvd.
Nutley, NJ 07110
O: 201-746-2852
C: 201-638-0484

[This e-mail message may contain privileged, confidential and/or proprietary information of Eisai. If you believe that it has been sent to you in error, please contact the sender immediately and delete the message including any attachments, without copying, using, or distributing any of the information contained therein. This e-mail message should not be interpreted to include a digital or electronic signature that can be used to authenticate an agreement, contract or other legal document, nor to reflect an intention to be bound to any legally-binding agreement or contract.]